Form 4: Ventyx Biosciences COO Matthew Moore Acquires Stock Options

Chief Operating Officer of Ventyx Biosciences, Matthew Richard Moore, reports acquisition of stock options.

Summary

• Matthew Richard Moore, the Chief Operating Officer of Ventyx Biosciences, filed a Form 4 with the SEC.
• The filing reports that Moore acquired stock options for 320,000 shares of Ventyx Biosciences common stock on May 16, 2024.
• The exercise price of the stock options is $4.98.
• The options vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on Moore's continued service to the company.
• The options expire on May 16, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting confidence in the company's future. The sentiment is neutral to positive.

Positives

• The acquisition of stock options by the COO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages long-term commitment from the COO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their executive compensation plans.
• The vesting schedule of 25% after one year followed by monthly vesting is a typical arrangement.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates